Results 161 to 170 of about 39,995 (281)
Combining Bayesian and Evidential Uncertainty Quantification for Improved Bioactivity Modeling. [PDF]
Khalil B +4 more
europepmc +1 more source
We developed a cost‐effective methylation‐specific droplet digital PCR multiplex assay containing tissue‐conserved and tumor‐specific methylation markers. The assay can detect circulating tumor DNA with high accuracy in patients with localized and metastatic colorectal cancer.
Luisa Matos do Canto +8 more
wiley +1 more source
Precis of <i>Evidential Pluralism in the Social Sciences</i>. [PDF]
Shan Y, Williamson J.
europepmc +1 more source
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice +16 more
wiley +1 more source
Medico-legal considerations in post-mortem imaging data: governance, ethics, and evidential use. [PDF]
Davendralingam N +3 more
europepmc +1 more source
Potential therapeutic targeting of BKCa channels in glioblastoma treatment
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak +4 more
wiley +1 more source
Rethinking misinformation through plausibility estimation and confidence calibration. [PDF]
Guigon V, Geay L, Charpentier CJ.
europepmc +1 more source
Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute +17 more
wiley +1 more source
The veridical Near-Death Experience Scale: construction and a first validation with human and artificial raters. [PDF]
Greyson B +11 more
europepmc +1 more source

